Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$7.79 USD
-0.14 (-1.77%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.82 +0.03 (0.39%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Atara Biotherapeutics, Inc. [ATRA]
Reports for Purchase
Showing records 1 - 20 ( 111 total )
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cell Therapy Deep Dive: Turning the Tide From Oncology to Autoimmune
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tab-Cel BLA Submitted to FDA for EBV+ PTLD; 1Q24 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pierre Fabre Labs Expanded Global Partnership Completed; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EMBOLD Trial Failure; 3Q23 Financials; Downgrading to Neutral Without PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tab-cel Biologics License Application Filing Pathway Clarified; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EMBOLD Primary Analysis 4Q23 Release; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Tab-Cel Data Presented; 1Q23 Financials; Increasing PT to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ebvallo European Launch in 1Q23; FY2022 Financials; Modulating PT Down to $27
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22: tab-cel BLA Filing Delayed to 2023. European Approval on the Horizon
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional ATA188 Open-Label Extension Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updated Multiple Sclerosis Data Indicate Progression-Free Prognosis
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Headcount Cuts; Pipeline Prioritization; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EMBOLD Interim Analysis Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R